Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/38981
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorSabogal Guáqueta, Angélica María-
dc.contributor.authorCarrillo Hormaza, Luis Carlos-
dc.contributor.authorCardona Gómez, Gloria Patricia-
dc.contributor.authorPérez Corredor, Paula Andrea-
dc.date.accessioned2024-04-11T00:02:12Z-
dc.date.available2024-04-11T00:02:12Z-
dc.date.issued2019-
dc.identifier.issn1420-3049-
dc.identifier.urihttps://hdl.handle.net/10495/38981-
dc.description.abstractABSTRACT: Alzheimer’s disease (AD) is the most common type of dementia and is the leading cause of disability in elderly people worldwide. Current pharmacological therapies do not cure the disease, and for this reason, some pharmacotherapy studies have investigated preventive treatments focused on modifiable nutritional factors such as diet. Quercetin (Qc) is a flavonoid found in fruits and vegetables that has several biological properties. In this study, we evaluated the effect of chronic oral quercetin administration (100 mg/kg) on neurodegeneration markers and cognitive and emotional deficits in a triple transgenic Alzheimer’s disease (3xTg-AD) mouse model using histological and behavioral analyses. Our results suggest that long-term (12 months) oral preventive treatment with quercetin has significant effects on β-amyloidosis reduction and tends to decrease tauopathy in the hippocampus and amygdala. These decreases positively affected the cognitive functional recovery (without modifying the emotional skills) of 3xTg-AD mice. These findings suggest that preventive and chronic administration of Qc might help to delay the development of histopathological hallmarks and cognitive function deficits in AD.spa
dc.format.extent10 páginasspa
dc.format.mimetypeapplication/pdf - application/epubspa
dc.language.isoengspa
dc.publisherMDPIspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titlePreventive Effect of Quercetin in a Triple Transgenic Alzheimer Disease Mice Modelspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Investigación en Sustancias Bioactivas (GISB)spa
dc.publisher.groupGrupo de Neurociencias de Antioquiaspa
dc.identifier.doi10.3390/molecules24122287-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.citationtitleMoleculesspa
oaire.citationstartpage1spa
oaire.citationendpage10spa
oaire.citationvolume24spa
oaire.citationissue12spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
oaire.fundernameUniversidad de Antioquia. Grupo de Neurociencias de Antioquia. Servicios de Extensión del Área de Neurobiología Celular y Molecularspa
dc.publisher.placeBasilea, Suizaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsEnfermedad de Alzheimer-
dc.subject.decsAlzheimer Disease-
dc.subject.decsAmyloid beta-Peptides - genética-
dc.subject.decsAmyloid beta-Peptides - genetics-
dc.subject.decsPrecursor de Proteína beta-Amiloide - genética-
dc.subject.decsAmyloid beta-Protein Precursor - genetics-
dc.subject.decsEncéfalo - efectos de los fármacos-
dc.subject.decsBrain - drug effects-
dc.subject.decsEncéfalo - patología-
dc.subject.decsBrain - pathology-
dc.subject.decsTrastornos del Conocimiento-
dc.subject.decsCognition Disorders-
dc.subject.decsModelos Animales de Enfermedad-
dc.subject.decsDisease Models, Animal-
dc.subject.decsHipocampo - efectos de los fármacos-
dc.subject.decsHippocampus - drug effects-
dc.subject.decsHipocampo - patología-
dc.subject.decsHippocampus - pathology-
dc.subject.decsAprendizaje por Laberinto - efectos de los fármacos-
dc.subject.decsMaze Learning - drug effects-
dc.subject.decsRatones-
dc.subject.decsMice-
dc.subject.decsRatones Transgénicos-
dc.subject.decsMice, Transgenic-
dc.subject.decsQuercetina - farmacología-
dc.subject.decsQuercetin - pharmacology-
dc.subject.decsProteínas tau - genética-
dc.subject.decstau Proteins - genetics-
dc.description.researchgroupidCOL0010359spa
dc.description.researchgroupidCOL0010744spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000544-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016229-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016564-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D001921-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003072-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D004195-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006624-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D018782-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D051379-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D008822-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011794-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016875-
dc.relation.ispartofjournalabbrevMoleculesspa
oaire.funderidentifier.rorRoR:03bp5hc83-
Aparece en las colecciones: Artículos de Revista en Farmacéutica y Alimentarias

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
CarrilloLuis_2019_Preventive_Effect_Quercetin_Alzheimer.pdfArtículo de investigación2 MBAdobe PDFVisualizar/Abrir
CarrilloLuis_2019_Preventive_Effect_Quercetin_Alzheimer.epubArtículo de investigación8.72 MBEPUBVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons